Evidence map›Paper›PMID 25220417›Full record

ArticleOncogene2015

Omega-3 fatty acids reduce obesity-induced tumor progression independent of GPR120 in a mouse model of postmenopausal breast cancer.

H Chung, Y S Lee, R Mayoral, D Y Oh, J T Siu, N J Webster, D D Sears, J M Olefsky, L G Ellies

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Lipid-based regulators of immunity.Bioengineering & translational medicine · 2022
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.Journal of experimental & clinical cancer research : CR · 2019
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. FFA4/GPR120: Pharmacology and Therapeutic Opportunities.Trends in pharmacological sciences · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

H ChungDivision of Endocrinology and Metabolism, Department of Medicine, University of California, La Jolla, CA, USA.
Y S LeeDivision of Endocrinology and Metabolism, Department of Medicine, University of California, La Jolla, CA, USA.
R Mayoral1] Division of Endocrinology and Metabolism, Department of Medicine, University of California, La Jolla, CA, USA [2] Biomedical Network Center for the study of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.
D Y OhDivision of Endocrinology and Metabolism, Department of Medicine, University of California, La Jolla, CA, USA.
J T SiuDepartment of Pathology, University of California at San Diego, La Jolla, CA, USA.
N J Webster1] Division of Endocrinology and Metabolism, Department of Medicine, University of California, La Jolla, CA, USA [2] Moores Cancer Center, University of California, La Jolla, CA, USA [3] San Diego VA Healthcare System, San Diego, CA, USA.
D D Sears1] Division of Endocrinology and Metabolism, Department of Medicine, University of California, La Jolla, CA, USA [2] Moores Cancer Center, University of California, La Jolla, CA, USA.
J M Olefsky1] Division of Endocrinology and Metabolism, Department of Medicine, University of California, La Jolla, CA, USA [2] Moores Cancer Center, University of California, La Jolla, CA, USA.
L G Ellies1] Department of Pathology, University of California at San Diego, La Jolla, CA, USA [2] Moores Cancer Center, University of California, La Jolla, CA, USA.
University of California, San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4M
Transcriptional Genomics CoreP01DK074868 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLASS, CHRISTOPHER K · 2007 to 2016
$16.6M
UCSD Biorepository Shared ResourceU54CA155435 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HERBST, KAREN LOUISE · 2011 to 2015
$9.1M
The Role of FSH in Female InfertilityP50HD012303 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LAWSON, MARK ANDREW · 1985 to 2020
$7.5M
Effects of Fractalkine on Beta Cell FunctionR01DK101395 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI OLEFSKY, JERROLD MICHAEL · 2014 to 2017
$1.6M
Role of the chronic inflammatory mediator NO in early mammary tumorigenesisK22CA118182 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELLIES, LESLEY G · 2006 to 2008
$442k
Alternative Splicing of the Insulin Receptor GeneI01BX000130 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI WEBSTER, NICHOLAS J · 2011 to 2013
–
BLRD VA I01 BX000130NCI NIH HHS K22 CA118182NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA23100NCI NIH HHS U54 CA155435NICHD NIH HHS P50 HD012303NIDDK NIH HHS P01 DK074868NIDDK NIH HHS P30 DK063491NIDDK NIH HHS R01 DK101395
6 · The paper itself

Abstract

Obesity and inflammation are both risk factors for a variety of cancers, including breast cancer in postmenopausal women. Intake of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) decreases the risk of breast cancer, and also reduces obesity-associated inflammation and insulin resistance, but whether the two effects are related is currently unknown. We tested this hypothesis in a postmenopausal breast cancer model using ovariectomized, immune-competent female mice orthotopically injected with Py230 mammary tumor cells. Obesity, whether triggered genetically or by high-fat diet (HFD) feeding, increased inflammation in the mammary fat pad and promoted mammary tumorigenesis. The presence of tumor cells in the mammary fat pad further enhanced the local inflammatory milieu. Tumor necrosis factor-alpha (TNF-α) was the most highly upregulated cytokine in the obese mammary fat pad, and we observed that TNF-α dose-dependently stimulated Py230 cell growth in vitro. An ω-3 PUFA-enriched HFD (referred to as fish oil diet, FOD) reduced inflammation in the obese mammary fat pad in the absence of tumor cells and inhibited Py230 tumor growth in vivo. Although some anti-inflammatory effects of ω-3 PUFAs were previously shown to be mediated by the G-protein-coupled receptor 120 (GPR120), the FOD reduced Py230 tumor burden in GPR120-deficient mice to a similar degree as observed in wild-type mice, indicating that the effect of FOD to reduce tumor growth does not require GPR120 in the host mouse. Instead, in vitro studies demonstrated that ω-3 PUFAs act directly on tumor cells to activate c-Jun N-terminal kinase, inhibit proliferation and induce apoptosis. Our results show that obesity promotes mammary tumor progression in this model of postmenopausal breast cancer and that ω-3 PUFAs, independent of GPR120, inhibit mammary tumor progression in obese mice.

Indexed as

AnimalsCells, CulturedDiet, High-FatDisease ProgressionFatty Acids, Omega-3FemaleMammary Neoplasms, ExperimentalMiceMice, Inbred C57BLMice, ObeseObesityOvariectomyPostmenopauseReceptors, G-Protein-CoupledFatty Acids, Omega-3FFAR4 protein, mouseReceptors, G-Protein-Coupled

Identifiers

PMID25220417
PMCPMC4362785
OpenAlexW2054093116

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.